In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Nippon Shinyaku Co., Ltd.

https://www.nippon-shinyaku.co.jp/english/

Latest From Nippon Shinyaku Co., Ltd.

Coronavirus Update: BioNTech And Fosun Launch Vaccine Trial In China

The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.

Coronavirus COVID-19 Vaccines

Roche Partners With UCB On Anti-Tau Alzheimer’s Drug

UCB gets $120m up front from Roche for option rights to UCB0107 and retains full rights to the drug in progressive supranuclear palsy.

Deals Business Strategies

Coronavirus Update: GSK Signs Non-Coronavirus Deal With CureVac On mRNA Vaccines

Deal brings in new funding and commercial partner for CureVac, and gives GSK greater stake in fast-developing mRNA field.

Coronavirus COVID-19 Deals

Coronavirus Update: Hardest Hit US States Will Test Moderna’s Vaccine

A round-up of developments in the COVID-19 vaccine field from Moderna, Fosun, Merck & Co and Medicago and more.

Coronavirus COVID-19 Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • NS Pharma, Inc.
UsernamePublicRestriction

Register